RTM added as distributor NeuraCeq®

Exciting news! Life Molecular Imaging’s NeuraCeq® 300 MBq/ml solution for injection (florbetaben 18F) will soon be available from Radboud Translational Medicine (RTM) in Nijmegen, The Netherlands. We're delighted to announce that the European Medicine Agency has approved the Type IB variation to the NeuraCeq EU dossier, adding RTM to the distribution network.

For more information on NeuraCeq®, including safety information, please visit: https://neuraceq.com/

RTM added as distributor NeuraCeq®

Other news

RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013

RTM supports Citryll’s imaging trial of [89Zr]Zr-DFO-CIT-013

Radboud Translational Medicine (RTM) is proud to announce its role as manufacturing partner for the...

Read more

Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers

Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers

Klaudia Cybulska (postdoc radiochemistry) has written an article about Huntington's Disease. Abstra...

Read more

First Patient Dosed with TLX250-CDx in Italy for ccRCC

First Patient Dosed with TLX250-CDx in Italy for ccRCC

The below product is manufactured at RTM First Patient dosed with TLX250-CDx in Italy for ccRCC Th...

Read more

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

Read more

Interested in a collaboration?

Contact us to discuss the possibilities.